Changeflow GovPing Healthcare & Life Sciences NCT07543419: Italian HS Secukinumab Observation...
Routine Notice Added Final

NCT07543419: Italian HS Secukinumab Observational Study

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH has registered an observational study (NCT07543419) evaluating treatment patterns with secukinumab in adult patients with moderate to severe hidradenitis suppurativa within the Italian population. The study aims to collect real-world data on treatment response, clinical characteristics, healthcare resource utilization, and economic impact of HS in Italy. No regulatory obligations are imposed by this database entry.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH has registered a new observational study (NCT07543419) titled 'Long Term Observational Study to Collect in a Real-world Population Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population.' The study will evaluate real-world evidence on secukinumab response, treatment patterns, clinical characteristics, healthcare resource utilization, and economic impact in Italian HS patients.

Pharmaceutical companies, clinical investigators, and healthcare providers with an interest in hidradenitis suppurativa research should note this trial registration. No compliance obligations or regulatory deadlines are associated with this database entry.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

Observational NCT07543419 Kind: OBSERVATIONAL Apr 21, 2026

Abstract

The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on secukinumab, healthcare resource utilization and the economic impact of HS in Italy.

Conditions: Hidradenitis Suppurativa

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 21st, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07543419

Who this affects

Applies to
Pharmaceutical companies Clinical investigators Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Treatment pattern analysis Real-world evidence collection
Geographic scope
IT IT

Taxonomy

Primary area
Healthcare
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!